研究通讯:特里弗卢诺米德不影响谷蛋白特异性T细胞在腹腔疾病中的活性 - 一个随机的,安慰剂控制的试验
Louise F Risnes1,2,3, Margit Brottveit4, Ida Robertsen5
1Norwegian Centre for Coeliac Disease Research, University of Oslo, Oslo, Norway.
Alimentary pharmacology & therapeutics
|October 22, 2025
概括
作为T细胞调节剂的Teriflunomide被测试在对心脏病的2a期试验中. 该研究发现T细胞活性没有显著的差异,得出结论说,teriflunomide在非饮食性胆固醇疾病治疗中无效.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结肠病是一种自身免疫性疾病,由摄入质引发.
- 目前的管理依赖于严格的,终身无质饮食.
- 需要新的非食治疗策略.
研究的目的:
- 评估特里弗卢诺米德在调节患有腹腔疾病的患者T细胞反应中的疗效.
- 评估特里弗卢诺米德作为治疗腹腔疾病的非食治疗的潜力.
主要方法:
- 一个2a期临床试验,涉及15名患有心脏病的患者.
- 托里弗卢诺米德或安慰剂的使用,包括加重剂量.
- 进行为期3天的口服谷蛋白挑战,然后对T细胞激活标记物进行监测.
主要成果:
- 在 teriflunomide 和安慰剂组之间没有观察到质特异性T细胞激活的显著差异.
- 在患有腹腔疾病的患者中,Teriflunomide在暴露于质后没有减弱T细胞反应.
结论:
- 泰里弗卢诺米德在降低T细胞活性的作用是不有效的.
- 这项研究表明,terriflunomide不是一种可行的非食治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
635
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
635
Drugs for Treatment of Ulcerative Colitis in IBD
452
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
452
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496


